The glucagonoma syndrome: Clinical and pathologic features in 21 patients

Medicine

Volumn 75, Issue 2, 1996, Pages 53-63

  Wermers, Robert A ^a   Fatourechi, Vahab ^a   Wynne, Alan G ^a   Kvols, Larry K ^a   Lloyd, Ricardo V ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; CARBOPLATIN; CHLOROZOTOCIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; INTERFERON; LOMUSTINE; MESSENGER RNA; SOMATOSTATIN DERIVATIVE; STREPTOZOCIN; TRICIRIBINE;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ANEMIA; BONE MARROW TOXICITY; CLINICAL ARTICLE; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIABETES MELLITUS; DIARRHEA; ENDOCRINE DISEASE; ERYTHEMA; FEMALE; GLUCAGON BLOOD LEVEL; GLUCAGONOMA; HUMAN; LABORATORY DIAGNOSIS; MALE; NEPHROTOXICITY; PANCREAS ISLET CELL TUMOR; PANCREAS RESECTION; PRIORITY JOURNAL; REVIEW; STOMATITIS; SYNDROME DELINEATION; TREATMENT OUTCOME; TUMOR LOCALIZATION;

ADULT; AGED; DIABETES MELLITUS; DIAGNOSIS, DIFFERENTIAL; DIARRHEA; ERYTHEMA; FEMALE; FOLLOW-UP STUDIES; GLUCAGONOMA; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; STOMATITIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0029916284     PISSN: 00257974     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005792-199603000-00002     Document Type: Review

References (93)

1. Abraira C, DeBartolo M, Katzen R, Lawrence AM. Disappearance of glucagonoma rash after surgical resection, but not during dietary normalization of serum amino acids. Am J Clin Nutr 39: 351-5, 1984.
2. Ajani JA, Levin B, Wallace S. Systemic and regional therapy of advanced islet cell tumors. Gastroenterol Clin North Am 18: 923-30, 1989.
3. Alsina AE, Bartus S, Hull D, Rosson R, Schweizer RT. Liver transplant for metastatic neuroendocrine tumor. J Clin Gastroenterol 12: 533-7, 1990.
4. Altimari AF, Bhoopalam N, O'Dorsio T, Lange CL, Sandberg L, Prinz RA. Use of a somatostatin analog (SMS 201-995) in the glucagonoma syndrome. Surgery 100: 989-96, 1986.
5. Axelrod L, Bush MA, Hirsch HJ, Loo SW. Malignant somatostatinoma: Clinical features and metabolic studies. J Clin Endocrinol Metab 52: 886-96, 1981.
6. Becker SW, Kahn D, Rothman S. Cutaneous manifestations of internal malignant tumors. Arch Dermatol Syphilol 45: 1069-80, 1942.
7. Bell GI, Sanchez-Pescador R, Laybourn PJ, Najarian RC. Exon duplication and divergence in the human preproglucagon gene. Nature 304: 368-71, 1983.
8. Bilbrey GL, Faloona GR, White MG, Knochel JP. Hyperglucagonemia of renal failure. J Clin Invest 53: 841-7, 1974.
9. Blackford S, Wright S, Roberts DL. Necrolytic migratory erythema without glucagonoma: The role of dietary essential fatty acids. Br J Dermatol 125: 460-2, 1991.
10. Bloomgarden ZT, Liljenquist JE, Cherrington AD, Rabinowitz D. Persistent stimulatory effect of glucagon on glucose production despite downregulation. J Clin Endocrinol Metab 47: 1152-5, 1978.
11. Boden G. Insulinoma and glucagonoma. Semin Oncol 14: 253-62, 1987.
12. Boden G. Glucagonomas and insulinomas. Gastroenterol Clin North Am 18: 831-45, 1989.
13. Boden G, Ryan IG, Eisenschmid BL, Shelmet JJ, Owen OE. Treatment of inoperable glucagonoma with the long-acting somatostatin analogue SMS 201-995. N Engl J Med 314: 1686-9, 1986.
14. Broder LE, Carter SK. Pancreatic islet cell carcinoma. II. Results of therapy with streptozotocin in 52 patients. Ann Intern Med 79: 108-18, 1973.
15. Buchanan KD. APUDomas and diabetes mellitus. Baillieres Clin Endocrinol Metab 6: 899-909, 1992.
16. Bukowski RM, Tangen C, Lee R, Macdonald JS, Einstein AB Jr, Peterson R, Fleming TR. Phase II trial of chlorozotocin and fluorouracil in islet cell carcinoma: A Southwest Oncology Group study. J Clin Oncol 10: 1914-8, 1992.
17. Capella C, Solcia E, Frigerio B, Buffa R, Usellini L, Fontana P. The endocrine cells of the pancreas and related tumours. Ultrastructural study and classification. Virchows Arch A Pathol Anat Histol 373: 327-52, 1977.
18. Cersosimo E, Pisters PW, Pesola G, McDermott K, Bajorunas D, Brennan MF. Insulin secretion and action in patients with pancreatic cancer. Cancer 67: 486-93, 1991.
19. Copeland GP, Leinster SJ, Davis JC, Hipkin LJ. Insulin resistance in patients with colorectal cancer. Br J Surg 74: 1031-5, 1987.
20. Delaney TJ, Uff JS. Necrolytic migratory erythema: Apparent response to oral omega-3 (marine) essential fatty acids. Br J Dermatol 123 Suppl 37: 107-9, 1990.
21. Doyle JA, Schroeter AL, Rogers RS III. Hyperglucagonaemia and necrolytic migratory erythema in cirrhosis - possible pseudoglucagonoma syndrome. Br J Dermatol 101: 581-7, 1979.
22. Elsborg L, Glenthoj A. Effect of somatostatin in necrolytic migratory erythema of glucagonoma. Acta Med Scand 218: 245-9, 1985.
23. Felig P, Wahren J, Hendler R. Influence of physiologic hyperglucagonemia on basal and insulin-inhibited splanchnic glucose output in normal man. J Clin Invest 58: 761-5, 1976.
24. Fraker DL, Norton JA. The role of surgery in the management of islet cell tumors. Gastroenterol Clin North Am 18: 805-30, 1989.
25. Glicksman AS, Rawson RW. Diabetes and altered carbohydrate metabolism in patients with cancer. Cancer 9: 1127-34, 1956.
26. Hendriks T. Radioimmunoassay of clinically meaningful components of circulating glucagon: Removal of big plasma glucagon prior to assay. Clin Chim Acta 140: 301-7, 1984.
27. Holmes A, Kilpatrick C, Proietto J, Green MD. Reversal of a neurologic paraneoplastic syndrome with octreotide (Sandostatin) in a patient with glucagonoma. Am J Med 91: 434-6, 1991.
28. Hunt SJ, Narus VT, Abell E. Necrolytic migratory erythema: Dyskeratotic dermatitis, a clue to early diagnosis. J Am Acad Dermatol 24: 473-7, 1991.
29. Jennings AS, Cherrington AD, Liljenquist JE, Keller U, Lacy WW, Chiasson JL. The roles of insulin and glucagon in the regulation of gluconeogenesis in the postabsorptive dog. Diabetes 26: 847-56, 1977.
30. Kahan RS, Perez-Figaredo RA, Neimanis A. Necrolytic migratory erythema. Distinctive dermatosis of the glucagonoma syndrome. Arch Dermatol 113: 792-7, 1977.
31. Kao PC, Jiang NS, Carpenter PC. Human corticotropin (ACTH) radioimmunoassay with synthetic 1-24 ACTH. Clin Chem 25: 1267-73, 1979.
32. Kaplan EL, Michelassi F. Endocrine tumors of the pancreas and their clinical syndromes. Surg Annu 18: 181-223, 1986.
33. Kasper CS, McMurry K. Necrolytic migratory erythema without glucagonoma versus canine superficial necrolytic dermatitis: Is hepatic impairment a clue to pathogenesis? J Am Acad Dermatol 25: 534-41, 1991.
34. Kerins C, Said SI. Hyperglycemic and glycogenolytic effects of vasoactive intestinal polypeptide. Proc Soc Exp Biol Med 142: 1014-7, 1973.
35. Kessinger A, Lemon HM, Foley JF. The glucagonoma syndrome and its management. J Surg Oncol 9: 419-24, 1977.
36. Khandekar JD, Oyer D, Miller HJ, Vick NA. Neurologic involvement in glucagonoma syndrome: Response to combination chemotherapy with 5-fluorouracil and streptozotocin. Cancer 44: 2014-6, 1979.
37. Kheir SM, Omura EF, Grizzle WE, Herrera GA, Lee I. Histologic variation in the skin lesions of the glucagonoma syndrome. Am J Surg Pathol 10: 445-53, 1986.
38. Klein S, Jahoor F, Baba H, Townsend CM Jr, Shepherd M, Wolfe RR. In vivo assessment of the metabolic alterations in glucagonoma syndrome. Metabolism 41: 1171-5, 1992.
39. Kloppel G, Heitz PU. Pancreatic endocrine tumors. Pathol Res Pract 183: 155-68, 1988.
40. Koch MB, Go VL, DiMagno EP. Can plasma human pancreatic polypeptide be used to detect diseases of the exocrine pancreas? Mayo Clin Proc 60: 259-65, 1985.
41. Kvols LK, Buck M. Chemotherapy of metastatic carcinoid and islet cell tumors. A review. Am J Med 82: 77-83, 1987.
42. Kvols LK, Buck M, Moertel CG, Schutt AJ, Rubin J, O'Connell MJ, Hahn RG. Treatment of metastatic islet cell carcinoma with a somatostatin analogue (SMS 201-995). Ann Intern Med 107: 162-8, 1987.
43. Larsson L-I. Endocrine pancreatic tumors. Hum Pathol 9: 401-16, 1978.
44. Leichter SB. Clinical and metabolic aspects of glucagonoma. Medicine (Baltimore) 59: 100-13, 1980.
45. Lewis AE. The glucagonoma syndrome. Int J Dermatol 18: 17-22, 1979.
46. Liljenquist JE, Mueller GL, Cherrington AD, Perry JM, Rabinowitz D. Hyperglycemia per se (insulin and glucagon withdrawn) can inhibit hepatic glucose production in man. J Clin Endocrinol Metab 48: 171-5, 1979.
47. Lindsey A, Santeusanio F, Braaten J, Faloona GR, Unger RH. Pancreatic alpha-cell function in trauma. JAMA 227: 757-61, 1974.
48. Lloyd RV, Jin L, Chandler WF, Horvath E, Stefaneanu L, Kovacs K. Pituitary specific transcription factor messenger ribonucleic expression in adenomatous and nontumorous human pituitary tissues. Lab Invest 69: 570-5, 1993.
49. Mallinson CN, Adrian TE, Hanley J, Bryant M, Bloom SR. Metabolic and clinical responses in patients with pancreatic glucagonomas (abstract). Ir J Med Sci 146 Suppl 1: 37-8, 1977.
50. Mallinson CN, Bloom SR, Warin AP, Salmon PR, Cox B. A glucagonoma syndrome. Lancet 2: 1-5, 1974.
51. Marinkovich MP, Botella R, Datloff J, Sangueza OP. Necrolytic migratory erythema without glucagonoma in patients with liver disease. J Am Acad Dermatol 32: 604-9, 1995.
52. McEntee GP, Nagorney DM, Kvols LK, Moertel CG, Grant CS. Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery 108: 1091-6, 1990.
53. McGavran MH, Unger RH, Recant L, Polk HC, Kilo C, Levin ME. A glucagon-secreting alpha-cell carcinoma of the pancreas. N Engl J Med 274: 1408-13, 1966.
54. Moertel CG, Hanley JA, Johnson LA. Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med 303: 1189-94, 1980.
55. Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 326: 519-23, 1992.
56. Montenegro F, Lawrence GD, Macon W, Pass C. Metastatic glucagonoma. Improvement after surgical debulking. Am J Surg 139: 424-7, 1980.
57. Morgan CR, Lazarow A. Immunoassay of insulin: Two antibody system; plasma insulin levels of normal, subdiabetic and diabetic rats. Diabetes 12: 115-26, 1963.
58. Moriarty GC, Moriarty CM, Sternberger LA. Ultrastructural immunocytochemistry with unlabeled antibodies and the peroxidase-antiperoxidase complex. A technique more sensitive than radioimmunoassay. J Histochem Cytochem 21: 825-33, 1973.
59. Mozell E, Stenzel P, Woltering EA, Rosch J, O'Dorisio TM. Functional endocrine tumors of the pancreas: Clinical presentation, diagnosis, and treatment. Curr Probl Surg 27: 301-86, 1990.
60. Muller WA, Faloona GR, Unger RH. Hyperglucagonemia in diabetic ketoacidosis. Its prevalence and significance. Am J Med 54: 52-7, 1973.
61. Murray-Lyon IM, Eddleston AL, Williams R, Brown M, Hogbin BM, Bennett A, Edwards JC, Taylor KW. Treatment of multiple-hormone-producing malignant islet-cell tumour with streptozotocin. Lancet 2: 895-8, 1968.
62. Nair KS. Hyperglucagonemia increases resting metabolic rate in man during insulin deficiency. J Clin Endocrinol Metab 64: 896-901, 1987.
63. National Diabetes Data Group. Diabetes in America: Diabetes data compiled 1984 (NIH Publication No. 85-1468). Bethesda, Maryland: United States Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute of Arthritis, Diabetes, and Digestive and Kidney Diseases, August 1985.
64. Norton JA, Kahn CR, Schiebinger R, Gorschboth C, Brennan MF. Amino acid deficiency and the skin rash associated with glucagonoma. Ann Intern Med 91: 213-5, 1979.
65. Permert J, Ihse I, Jorfeldt L, von Schenck H, Arnqvist HJ, Larsson J. Pancreatic cancer is associated with impaired glucose metabolism. Eur J Surg 159: 101-7, 1993.
66. Quin JD, Marshall DA, Fisher BM, MacCuish AC. Metastatic pancreatic polypeptide producing tumour presenting with diabetes mellitus. Scott Med J 36: 143, 1991.
67. Rader DL, Martin JK Jr, Scheithauer BW. Cytoreduction surgery for metastatic glucagonoma. A clinicopathologic study with special reference to the utility of immunocytochemistry and ultrastructure in diagnosis. Minn Med 67: 483-5, 516, 1984.
68. Raskin P, Unger RH. Effects of exogenous hyperglucagonemia in insulin-treated diabetics. Diabetes 26: 1034-9, 1977.
69. Raskin P, Unger RH. Hyperglucagonemia and its suppression. Importance in the metabolic control of diabetes. N Engl J Med 299: 433-6, 1978.
70. Reyes-Govea J, Holm A, Aldrete JS. Response of glucagonomas to surgical excision and chemotherapy. Report of two cases and review of the literature. Am Surg 55: 523-7, 1989.
71. Rocha DM, Santeusanio F, Faloona GR, Unger RH. Abnormal pancreatic alpha-cell function in bacterial infections. N Engl J Med 288: 700-3, 1973.
72. Rosenbaum A, Flourie B, Chagnon S, Blery M, Modigliani R. Octreotide (SMS 201-995) in the treatment of metastatic glucagonoma: Report of one case and review of the literature. Digestion 42: 116-20, 1989.
73. Roth E, Muhlbacher F, Karner J, Hamilton G, Funovics J. Free amino acid levels in muscle and liver of a patient with glucagonoma syndrome. Metabolism 36: 7-13, 1987.
74. Sack GH Jr, Levin J, Bell WR. Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: Clinical, pathophysiologic, and therapeutic features. Medicine (Baltimore) 56: 1-37, 1977.
75. Salter JM, Davidson IWF, Best CH. The pathologic effects of large amounts of glucagon. Diabetes 6: 248-52, 1957.
76. Salter JM, Ezrin C, Laidlaw JC, Gornall AG. Metabolic effects of glucaeon in human subjects. Metabolism 9: 753-68, 1960.
77. Shepherd ME, Raimer SS, Tyring SK, Smith EB. Treatment of necrolytic migratory erythema in glucagonoma syndrome. J Am Acad Dermatol 25: 925-8, 1991.
78. Sherwin RS, Fisher M, Hendler R, Felig P. Hyperglucagonemia and blood glucose regulation in normal, obese and diabetic subjects. N Engl J Med 294: 455-61, 1976.
79. Shihabi ZK, Scaro J. Liquid-chromatographic assay of urinary 5-hydroxy-3-indoleacetic acid, with electrochemical detection. Clin Chem 26: 907-9, 1980.
80. Sizemore GW, Go VL, Kaplan EL, Sanzenbacher LZ, Holtermuller KH, Arnaud CD. Relations of calcitonin and gastrin in the Zollinger-Ellison syndrome and medullary carcinoma of the thyroid. N Engl J Med 288: 641-4, 1973.
81. Stacpoole PW. The glucagonoma syndrome: Clinical features, diagnosis, and treatment. Endocr Rev 2: 347-61, 1981.
82. Sweet RD. A dermatosis specifically associated with a tumour of pancreatic alpha cells. Br J Dermatol 90: 301-8, 1974.
83. Unger RH. Glucagon and the insulin:glucagon ratio in diabetes and other catabolic illnesses. Diabetes 20: 834-8, 1971.
84. Unger RH, Orci L. Physiology and pathophysiology of glucagon. Physiol Rev 56: 778-826, 1976.
85. Valette PJ, Souquet JC. Pancreatic islet cell tumors metastatic to the liver: Treatment by hepatic artery chemo-embolization. Horm Res 32: 77-9, 1989.
86. Vinik AI, Moattari AR. Treatment of endocrine tumors of the pancreas. Endocrinol Metab Clin North Am 18: 483-518, 1989.
87. Wilkinson DS. Necrolytic migratory erythema with carcinoma of the pancreas. Trans St Johns Hosp Dermatol Soc 59: 244-50, 1973.
88. Willerson JT, Hutcheson DR, Leshin SJ, Faloona GR, Unger RH. Serum glucagon and insulin levels and their relationship to blood glucose values in patients with acute myocardial infarction and acute coronary insufficiency. Am J Med 57: 747-52, 1974.
89. Wilmore DW, Lindsey CA, Moyland JA, Faloona GR, Pruitt BA, Unger RH. Hyperglucagonaemia after burns. Lancet 1: 73-5, 1974.
90. Wise JK, Hendler R, Felig P. Influence of glucocorticoids on glucagon secretion and plasma amino acid concentrations in man. J Clin Invest 52: 2774-82, 1973.
91. Wolfe BM, Culebras JM, Aoki TT, O'Connor NE, Finley RJ, Kaczowka A, Moore FD. The effects of glucagon on protein metabolism in normal man. Surgery 86: 248-57, 1979.
92. Wynick D, Williams SJ, Bloom SR. Symptomatic secondary hormone syndromes in patients with established malignant pancreatic endocrine tumors. N Engl J Med 319: 605-7, 1988.
93. Yaksh TL, Michener SR, Bailey JE, Harty GJ, Lucas DL, Nelson DK, Roddy DR, Go VL. Survey of distribution of substance P, vasoactive intestinal polypeptide, cholecystokinin, neurotensin, Met-enkephalin, bombesin and PHI in the spinal cord of cat, dog, sloth and monkey. Peptides 9: 357-72, 1988.